Emergent Biosolutions (EBS) said Tuesday it has secured contract modifications totaling more than $250 million from the US Department of Health and Human Services' Administration for Strategic Preparedness and Response.
The contracts include $30 million to supply Cyfendus this year; $99.9 million for ACAM2000; and two new contract options worth $122.9 million to supply VIGIV and BAT to the Strategic National Stockpile, the company said.
Shares of Emergent Biosolutions were up almost 2% in Tuesday premarket activity.
Price: 7.20, Change: +0.14, Percent Change: +1.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments